Nurix therapeutics reports fourth quarter and fiscal year 2023 financial results and provides a corporate update
Nx-5948 received fast track designation from the fda nx-5948 showed positive results in phase 1 clinical trial establishing a robust foundation for advancement in cll licensed to gilead a new development candidate, nx-0479/gs-6791, a targeted protein degrader of irak-4 for rheumatoid arthritis formed strategic collaboration with seagen (now pfizer) to advance a portfolio of degrader-antibody conjugates based on our industry-leading deligase platform achieved $100 million in non-dilutive capital from partners in 2023, including $60 million upfront from seagen and $40 million in success-based milestones and licensing fees from gilead and sanofi maintained strong financial position with cash and investments of $295.3 million san francisco, feb. 15, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the fiscal quarter and fiscal year ended november 30, 2023, and provided a corporate update. “building on a very successful 2023, marked by impressive clinical data for both nx-5948 and nx-2127, nurix has hit the ground running in 2024, with plans to accelerate enrollment in the nx-5948 leukemia and lymphoma program and enable development in inflammatory diseases,” said arthur t.
NRIX Ratings Summary
NRIX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission